Gerald Chi
scholar.google.com
0000-0002-8371-1689
122 papers found
Refreshing results…
Scleroderma and failed response to alefacept
d-Dimer elevation and adverse outcomes
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy
The Relationship Between Patency of the Culprit Artery on Admission and Electrolyte Changes in Anterior STEMI - Analysis From the EMBRACE STEMI Clinical Trial
Abstract 19208: Extended Duration Betrixaban Reduces the Risk of Stroke vs Standard Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Substudy.
Abstract 18092: The Relationship Between Patency of the Culprit Artery on Admission and Electrolyte Changes in Anterior STEMI - Analysis From the EMBRACE STEMI Clinical Trial.
Abstract 19875: IMPROVEDD Score: Addition of D-Dimer to the IMPROVE Score Improves Venous Thromboembolism Risk Stratification. An APEX Trial Substudy.
The Association Between Left Ventricular Mass and Measures of Infarct Size in Anterior St-Segment Elevation Myocardial Infarction: Insights From the Embrace Stemi Clinical Trial
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis
Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial)
Characterization of Access vs. Non-Access Site Bleeding Following PCI in Patients With Atrial Fibrillation
D-dimer concentration is associated with increased risk for VTE and greater absolute benefit of extended prophylaxis with betrixaban in acutely III medical patients: insights from the APEX trial
Betrixaban Reduces Not Only the Presence of Thrombus but Also Extent of Thrombus: An APEX Trial Substudy
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with stroke among hospitalized medical patients: an APEX trial substudy
History of venous thromboembolism is associated with higher risk for recurrent venous thromboembolism: insights from the APEX trial
P4565 Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy.
P5600 History of venous thromboembolism is associated with higher risk for recurrent venous thromboembolism: insights from the APEX trial.
Abstract 20322: Extended-Duration Betrixaban Reduces the Risk of Venous Thromboembolism-Related Rehospitalization Among Acutely Ill Hospitalized Medical Patients: An APEX Trial Substudy.
Abstract 19512: Characterization of Access vs. Non-Access Site Bleeding Following PCI in Patients With Atrial Fibrillation.
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy
Missing publications? Search for publications with a matching author name.